Specific desensitization of sulfonylurea- but not imidazoline-induced insulin release after prolonged tolbutamide exposure

被引:15
作者
McClenaghan, NH [1 ]
Ball, AJ [1 ]
Flatt, PR [1 ]
机构
[1] Univ Ulster, Sch Biomed Sci, Coleraine BT52 1SA, Londonderry, North Ireland
关键词
sulfonylurea; imidazoline; desensitization; clonal pancreatic beta cells; insulin release;
D O I
10.1016/S0006-2952(00)00579-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Functional effects of prolonged exposure to the sulfonylurea, tolbutamide, were examined in the clonal electrofusion-derived BRIN-BD11 cell Line. In acute 20-min incubations, 50-400 muM tolbutamide stimulated a dose-dependent increase (P < 0.01) in insulin release at both non-stimulatory (1.1 mM) and stimulatory (8.4 mM) glucose. Culture with 100 <mu>M tolbutamide (18 hr) caused a marked (67%) decrease in subsequent insulin-secretory responsiveness to acute challenge with 200 muM tolbutamide, though notably, tolbutamide culture exerted no influence on 200 muM efaroxan-induced insulin secretion. Duration of exposure (3-18 hr) to 100 muM tolbutamide in culture also time-dependently influenced subsequent responsiveness to acute tolbutamide challenge, with progressive 47-58% decreases from 6-18 hr (P < 0.001). Similarly, 6- to 18-hr culture with 100 <mu>M efaroxan specifically desensitized efaroxan-induced insulin release. Tolbutamide- and efaroxan-induced desensitization exhibited a time-dependent reversibility, with a sustained return to full insulin-secretory responsiveness by 12 hr. Notably, 18-hr culture with tolbutamide or efaroxan did not significantly affect insulinotropic responses to 16.7 mM glucose, 10 mM 2-ketoisocaproic acid, 10 mM alanine, 10 mM arginine, or 30 mM KCl. Diverse inhibitory actions of tolbutamide or efaroxan culture on late events in stimulus-secretion coupling reveal that drug desensitization is both a specific and important phenomenon. As such, the model system described could prove an important tool in determining the complex modes of action of established and novel clinically useful insulinotropic compounds. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:527 / 536
页数:10
相关论文
共 60 条
[1]   Molecular biology of adenosine triphosphate-sensitive potassium channels [J].
Aguilar-Bryan, L ;
Bryan, J .
ENDOCRINE REVIEWS, 1999, 20 (02) :101-135
[2]   High-fat hypercaloric diet induces obesity, glucose intolerance and hyperlipidemia in normal adult male Wistar rat [J].
Akiyama, T ;
Tachibana, I ;
Shirohara, H ;
Watanabe, N ;
Otsuki, M .
DIABETES RESEARCH AND CLINICAL PRACTICE, 1996, 31 (1-3) :27-35
[3]   A NEW HYPOGLYCEMIC AGENT, A-4166, INHIBITS ATP-SENSITIVE POTASSIUM CHANNELS IN RAT PANCREATIC BETA-CELLS [J].
AKIYOSHI, M ;
KAKEI, M ;
NAKAZAKI, M ;
TANAKA, H .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1995, 268 (02) :E185-E193
[4]   Promiscuous coupling between the sulphonylurea receptor and inwardly rectifying potassium channels [J].
Ammala, C ;
Moorhouse, A ;
Gribble, F ;
Ashfield, R ;
Proks, P ;
Smith, PA ;
Sakura, H ;
Coles, B ;
Ashcroft, SJH ;
Ashcroft, FM .
NATURE, 1996, 379 (6565) :545-548
[5]   Correlating structure and function in ATP-sensitive K+ channels [J].
Ashcroft, FM ;
Gribble, FM .
TRENDS IN NEUROSCIENCES, 1998, 21 (07) :288-294
[6]   Identification of the high-affinity tolbutamide site on the SUR1 subunit of the KATP channel [J].
Ashfield, R ;
Gribble, FM ;
Ashcroft, SJH ;
Ashcroft, FM .
DIABETES, 1999, 48 (06) :1341-1347
[7]  
Bailey CJ, 1997, TXB DIABETES, P231
[8]   Antazoline increases insulin secretion and improves glucose tolerance in rats and dogs [J].
Berdeu, D ;
Puech, R ;
Ribes, G ;
LoubatieresMariani, MM ;
Bertrand, G .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 324 (2-3) :233-239
[9]   THE ALPHA-2-ADRENOCEPTOR ANTAGONIST EFAROXAN MODULATES K+ATP CHANNELS IN INSULIN-SECRETING CELLS [J].
CHAN, SLF ;
DUNNE, MJ ;
STILLINGS, MR ;
MORGAN, NG .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, 204 (01) :41-48
[10]   ATP-sensitive potassium channels and efaroxan-induced insulin release in the electrofusion-derived BRIN-BD11 β-cell line [J].
Chapman, JC ;
McClenaghan, NH ;
Cosgrove, KE ;
Hashmi, MN ;
Shepherd, RM ;
Giesberts, AN ;
White, SJ ;
Ämmälä, C ;
Flatt, PR ;
Dunne, MJ .
DIABETES, 1999, 48 (12) :2349-2357